Given the finding that tofogliflozin lowers albuminuria in type 2 diabetes patients, 40% of which effect could be attributable to its beneficial action on tubulointerstitial damage, as evidenced by decrease of urinary l-FABP (Yanagisawa et al. 2020), our present study suggests that empagliflozin may reduce proteinuria in db/db mice partly via attenuation of the tubulointerstitial injury caused by the AGE-RAGE-ROS axis. Here, AGER is linked to type 2 diabetes mellitus.